WO1996002272A3 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number
WO1996002272A3
WO1996002272A3 PCT/EP1995/002885 EP9502885W WO1996002272A3 WO 1996002272 A3 WO1996002272 A3 WO 1996002272A3 EP 9502885 W EP9502885 W EP 9502885W WO 1996002272 A3 WO1996002272 A3 WO 1996002272A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
host
autoimmune diseases
preventing
treatment
infecting
Prior art date
Application number
PCT/EP1995/002885
Other languages
French (fr)
Other versions
WO1996002272A2 (en )
Inventor
Erna Moeller
Cecilia Soederberg
Original Assignee
Erna Moeller
Cecilia Soederberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088Varicella-zoster virus, e.g. cytomegalovirus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Autoimmune diseases such as graft versus host disease, are associated with the development of an autoimmune response, such as autoantibodies raised against a host protein carried by an infecting microorganism. The invention provides methods of combatting autoimmune diseases by preventing the organism from infecting the host, by vaccination, by preventing the antibodies from effecting tissue damage, and by preventing the organisms from initiating an immune response in the host. The invention includes modified microorganisms which either lack the host protein or in which the host protein is non-immunogenic.
PCT/EP1995/002885 1994-07-20 1995-07-20 Treatment of autoimmune diseases WO1996002272A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB9414652A GB9414652D0 (en) 1994-07-20 1994-07-20 Method of treatment
GB9414652.9 1994-07-20

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19950927691 EP0773793A1 (en) 1994-07-20 1995-07-20 Treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
WO1996002272A2 true WO1996002272A2 (en) 1996-02-01
WO1996002272A3 true true WO1996002272A3 (en) 1996-03-21

Family

ID=10758627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002885 WO1996002272A3 (en) 1994-07-20 1995-07-20 Treatment of autoimmune diseases

Country Status (3)

Country Link
EP (1) EP0773793A1 (en)
GB (1) GB9414652D0 (en)
WO (1) WO1996002272A3 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334301A1 (en) * 1988-03-21 1989-09-27 Chiron Viagene, Inc. Recombinant retroviruses
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
US5252603A (en) * 1989-03-15 1993-10-12 Cetus Corporation Immunosuppressive analogues and derivatives of succinylacetone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334301A1 (en) * 1988-03-21 1989-09-27 Chiron Viagene, Inc. Recombinant retroviruses
US5252603A (en) * 1989-03-15 1993-10-12 Cetus Corporation Immunosuppressive analogues and derivatives of succinylacetone
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOHAN NEYTS ET AL.: "Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate", VIROLOGY, vol. 189, no. 1, pages 48 - 58 *
M. O. WESTENDORP ET AL.: "Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120", NATURE, vol. 375, pages 497 - 500 *
PENTTI UKKONEN: "Production of polyclonal antisera against cytomegalovirus and varicella-zoster virus by use of affinity-purified viral antigens", APMIS (ACTA PATHOL MICROBIOL IMMUNOL SCAND), vol. 97, no. 3, pages 267 - 273 *
TROND FLAEGSTAD ET AL.: "Inoculation with BK virus may break immunological tolerance to histone and DNA antigens", PROC. NATL. ACAD. SCI. USA, vol. 85, no. 21, pages 8171 - 8175 *

Also Published As

Publication number Publication date Type
EP0773793A1 (en) 1997-05-21 application
GB9414652D0 (en) 1994-09-07 grant
WO1996002272A2 (en) 1996-02-01 application

Similar Documents

Publication Publication Date Title
WO1997048370A3 (en) Vaccines comprising synthetic genes
WO2002062981A1 (en) A yeast human immunoregulator and the method for preparing it
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2002021141A3 (en) Methods and compositions for diseases associated with amyloidosis
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO1999041383A8 (en) Antigen library immunization
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
RU2221809C2 (en) Method for preparing natural humanized antibody
CA2145505A1 (en) Microparticle preparations made from biodegradable copolymers
Roberts Human gene transfer test approved
WO2002008273A3 (en) 47508, a novel human histone deacetylase family member and uses thereof
CA2369292A1 (en) Method of modulating the activity of functional immune molecules
WO2001062794A3 (en) 18607, a human calcium channel
RU2207878C2 (en) "humanized" antibodies raised against human gp39, compositions comprising these antibodies and their therapeutic using
RU2218405C2 (en) Protein eliciting activity of d-pantolactone hydrolase, nucleic acid encoding thereof, vector, strain, method for preparing protein, method for preparing d-pantolactone
WO2004074440A3 (en) Preparation of organisms with faster growth and/or higher yield
EP1264843A3 (en) 38554, 57301 and 58324, Human organic ion transporters and uses therefor
RU2481393C2 (en) New bacteria causing diseases of poultry and vaccine produced from them
WO1996040945A3 (en) Nucleic acid respiratory syncytial virus vaccines
EP0332424A3 (en) Chimeric antibodies directed against human carcinoembryonic antigen
Isaeva et al. Immunological Action of Bacteria(and Their Products) on Fish
EP1225182A3 (en) Human phospholipid transporter
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CA2013544A1 (en) Retinoblastoma gene product antibodies and uses therefor
Janssens Scientific perspectives on biologicals research.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995927691

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: US

Ref document number: 1997 776012

Date of ref document: 19970314

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995927691

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1995927691

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995927691

Country of ref document: EP